TGFβ for Immuno-Oncology Drug Development Conference 2021

Jan 18, 2021

January 2021, Virtual
Poster: AdAPT-001, a replication competent type 5 adenovirus carrying a TGF-β “trap”, reverses resistance to a PD-L1 inhibitor in an immunocompetent mouse model